Platelets are crucial for preventing excessive blood loss at sites of injury by plugging holes in damaged blood vessels through thrombus formation. Platelet thrombi can, however, cause heart attack or stroke by blocking diseased vessels upon rupture of atherosclerotic plaques. Current anti-platelet therapy is not effective in all patients and carries a risk of bleeding. As such, a major goal in platelet research is to identify new drug targets to specifically inhibit platelets in disease processes. Tetraspanins are potential candidates because of their capacity to regulate other proteins in microdomains, and their defined roles in cell adhesion and signalling. In the last 6 years, analyses of tetraspanin-deficient mice have suggested that tetraspanins are indeed important for fine-tuning platelet responses. The future characterization of novel regulatory mechanisms in tetraspanin microdomains may lead to new drug targets for the prevention and treatment of heart attack and stroke.
Introduction
Platelets are essential for haemostasis, which is the body's normal response to ensure blood vessel integrity and blood fluidity. However, they are also central to arterial thrombosis, namely the formation of a blood clot, or thrombus, which can cause death by blocking the flow of blood to part of an organ such as the heart or brain. Arterial thrombosis is usually the culmination of the process of atherosclerosis, which is the progressive thickening and hardening of the arterial wall due to the deposition of fatty deposits and recruitment of inflammatory leucocytes under the endothelium, to form atheroma [1] . The rupture of atheroma, and subsequent blockage of the artery by activated platelets, can result in heart attack or stroke. British Heart Foundation statistics (http://www.heartstats.org) show that heart attack and stroke are major killers in the UK, accounting for 18 and 9 % of all deaths respectively in addition to causing severe morbidity and economic costs. The importance of platelets in these diseases is highlighted by the fact that anti-platelet drugs are current treatments. However, not all patients respond well to anti-platelet therapies, and there is also a risk of bleeding that can lead to fatal haemorrhage. Thus a major goal in platelet research is to identify new drug targets that preferentially inhibit the role of platelets in disease [2] .
Platelets are small, anuclear cells that are generated by bone marrow megakaryocytes and then circulate in the bloodstream in a quiescent state. Following damage to the blood vessel wall, platelets undergo explosive activation leading to the formation of a vascular plug, or thrombus, and cessation of bleeding. This rapid response is mediated by a large repertoire of cell-surface molecules, including integrins, Ig superfamily proteins, leucine-rich repeat and G-proteincoupled receptors (Figure 1 ). These receptor types interact with a diverse range of ligands such as subendothelial matrix proteins, soluble agonists and surface molecules on other cells [3] . Critical to the understanding of platelet function is the way in which these receptors are organized and the manner whereby their signals interact to promote activation.
The tetraspanins are a superfamily of cell-surface glycoproteins that are characterized by four transmembrane domains, intracellular N-and C-termini, and conserved sequence motifs within the larger of two extracellular regions [4] [5] [6] . Their biological functions are yet to be fully understood, but a fundamental role is supported by striking phenotypes in tetraspanin-deficient humans, mice, flies, worms, fungi and plants [4] . Tetraspanins are thought to function by selfassociating to form a novel type of membrane microdomain which is distinct from lipid raft microdomains [7] . They are not generally believed to have ligands or to serve as surface receptors, but instead modify the biosynthetic maturation, trafficking, signalling and adhesion of their socalled partner proteins, including integrins, Ig superfamily proteins and G-protein-coupled receptors. These partner proteins appear to be recruited to the microdomain by specific tetraspanins [4] [5] [6] . Microscopy studies have led to a dynamic model whereby individual tetraspanins patrol the membrane in complex with a relatively small number of associated tetraspanins and partner proteins, but at times can become confined in larger tetraspanin microdomains that extend over a few hundred nanometres [4] . Therefore one can speculate that individual tetraspanin microdomains may function as platforms on which different receptors, signalling proteins and their regulatory molecules may be compartmentalized to co-operate as a functional unit. The molecules depicted, from left to right, are the leucine-rich repeat GPIb-IX-V complex, which is a receptor for vWF, the Ig superfamily protein GPVI, a receptor for collagen and laminin, tetraspanins, integrins, seven-transmembrane G-protein-coupled receptors and the transmembrane protein tyrosine phosphatase CD148, which has extracellular fibronectin type III domains and an intracellular phosphatase domain. Predicted N-linked glycosylation sites are indicated by filled ovals and O-linked glycosylation on GPIb-IX-V and GPVI by narrow ovals. The copy number of each protein, in terms of molecules per platelet, is indicated in parentheses. The relative expression levels of tetraspanins CD9, CD151, Tspan9 and CD63 have been estimated at 50:7:3:1 respectively [11] , although only CD9 has been quantified in terms of number of surface copies per platelet.
The platelet surface
Most of the major surface proteins that promote platelet activation and thrombus formation appear to have now been identified using monoclonal antibodies and more recently proteomics [8, 9] . Unlike in most other cell types, the actual numbers of many of these proteins, in terms of copies per platelet, have been quantified (Figure 1 ). Furthermore, their important roles in platelet activation are being characterized through the study of patients with platelet-based bleeding disorders and gene-deficient mice [3] .
The current model of platelet activation in response to blood vessel injury has been recently reviewed [3] . To summarize, damage to the endothelial cells lining the vessel exposes subendothelial matrix proteins including vWF (von Willebrand factor), collagen, laminin and fibronectin. Under the high shear environment in small arteries and arterioles, collagen-bound vWF is particularly important in allowing transient platelet adhesion, or rolling, via interaction with the highly expressed GP (glycoprotein) Ib-IX-V complex of leucine-rich repeat family proteins. This allows engagement of the platelet collagen receptor GPVI, a member of the Ig superfamily with a relatively low affinity for collagen.
GPVI transmits powerful activating signals via an ITAM (immunoreceptor tyrosine-based activation motif) contained within the associated FcRγ chain, which recruits cytoplasmic protein tyrosine kinases [3] . Initiation of this signalling pathway is critically dependent on positive regulators such as the transmembrane protein tyrosine phosphatase CD148 [10] . GPVI/FcRγ signalling, in combination with the somewhat weaker tyrosine kinase activation by GPIb-IX-V, causes calcium mobilization, platelet shape change from discoid to spherical, 'inside-out' activation of integrins to a high-affinity state and the release of secondary mediators such as ADP and thromboxane A 2 [3] . Activation of the collagenbinding integrin α2β1 results in firm platelet adhesion to collagen, and this is supported by integrins α5β1 and α6β1, which bind to fibronectin and laminin respectively. Activation of the major platelet integrin αIIbβ3, which is the most highly expressed protein on the platelet surface, is essential for platelet-platelet interaction and subsequent thrombus formation. This is achieved by blood plasma fibrinogen binding to two αIIbβ3 molecules on adjacent platelets, thus forming a bridge between two platelets. The secondary mediators ADP and thromboxane A 2 , together with thrombin that is generated by the coagulation cascade, synergistically reinforce platelet activation, and act to recruit other platelets, by binding to their G protein-coupled receptors on platelets: P2Y 1 and P2Y 12 for ADP, the thromboxane A 2 receptor TP and PAR (protease-activated receptor)-1 and PAR-4 for thrombin [3] . The importance of these secondary mediators is highlighted by the fact that current anti-platelet therapy for heart disease and stroke patients targets the ADP pathway via the P2Y 12 antagonist clopidogrel, and the thromboxane A 2 pathway via the cyclo-oxygenase COX1 inhibitor aspirin, which prevents thomboxane A 2 production [2] .
Clues to tetraspanin function on platelets
Quantification of platelet tetraspanins suggests that they cover a substantial portion of the platelet surface, and tetraspanin CD9 appears to be the second most highly expressed surface protein. Four additional tetraspanins, CD63, CD151, Tspan9 and Tspan32 (also named TSSC6), have been definitively shown to be expressed on platelets using antibodies, but appear to be at levels of 15 % or less than those of CD9 [11] . In addition, ten tetraspanins were identified in the most extensive proteomic analysis of human platelet membranes to date [8, 12] , and as many as 18 are potentially expressed on the basis of their identification in mouse megakaryocytes at the mRNA level [11] .
The platelet tetraspanin field was initiated by the finding that CD9 antibodies had the rather unusual property of inducing platelet activation, an effect that was dependent on simultaneous engagement of Fcγ RIIA, the low-affinity receptor for IgG [13] . Our current understanding of tetraspanins, as the building blocks of microdomains containing a variety of proteins, would suggest that such platelet activation is a consequence of cross-linking tetraspaninassociated signalling proteins with the ITAM-containing Fcγ RIIA. Such a theory is consistent with the finding that antibodies to another tetraspanin, CD151, also induce platelet activation [13] .
More recent studies have investigated tetraspanin function using platelets from tetraspanin-deficient mice. Possibly the most surprising result of all these studies was the very subtle phenotype observed in the absence of CD9, since it is expressed at such high levels [14] . No phenotype was observed using the common platelet function tests, namely in vitro platelet aggregation to a range of agonists, clot retraction and thrombus formation under flow. Tail bleeding time, which is a rather crude in vivo assay that in our hands only reliably detects major bleeding phenotypes, also showed no phenotype. However, a mild phenotype was revealed by a cutting-edge intravital microscopy technique that measures thrombus formation in carotid arteries damaged with ferric chloride. While initial thrombus formation was normal, thrombi in CD9-deficient mice failed to embolize normally with the result that they were almost 50 % larger at the end of the experiment and so more likely to block the vessel. Consistent with the idea of CD9 as a negative regulator on platelets, fibrinogen binding of integrin αIIbβ3 in response to three different platelet agonists was mildly increased in the absence of CD9, suggesting that CD9 limits inside-out activation of this integrin [14] . A minor phenotype in the absence of CD9 is not unique to platelets; CD9 is highly expressed on a large number of different cell types, but the only major phenotype is female infertility due to a failure of CD9-deficient eggs to fuse with sperm, although the mechanism is yet to be clarified [4] .
Studies of CD63-deficient mice also failed to yield a severe platelet phenotype [15] . This was somewhat surprising because of the restricted localization of CD63 to platelet α-granules and dense granules, which translocate to the plasma membrane upon activation, releasing adhesion molecules, matrix proteins and secondary mediators that are essential for thrombus formation. Granule translocation and release appeared to be normal in the absence of CD63, as was in vitro thrombus formation under flow and in vivo thrombus formation using the ferric chloride model [15] . The only phenotype observed was a mild in vitro hyperaggregation in response to all agonists tested, suggesting that CD63, like CD9, might have a weak inhibitory role on platelets. The major phenotype detected in CD63-deficient mice was an altered water balance, possibly due to defective trafficking within cells of the kidney collecting ducts [15] .
The mild phenotypes observed in CD9-and CD63-deficient platelets were demonstrated quite recently. Much more substantial, however, were the platelet phenotypes in mice deficient for CD151 and Tspan32. These findings, published by Denise Jackson's group, were the first to establish that tetraspanins were essential for normal platelet function. In the first study that reported the generation of CD151-deficient mice, the tail bleeding assay was used to show slightly longer bleeding times, leading to the loss of three times more blood and a 7-fold increase in re-bleeding [16] . A follow-up report suggested a defect in outside-in integrin αIIbβ3 activation in CD151-deficient platelets, with a consequence of profoundly defective platelet spreading and delayed clot retraction [17] . A more recent in vivo study demonstrated smaller and more unstable thrombi in CD151-deficient mice, with longer times to vessel blockage [18] . These data were generated by intravital microscopy using both ferric chloride and a less severe laser injury model. Moreover, platelet depletion and reconstitution experiments proved that impaired thrombus formation was due to the absence of CD151 from platelets rather than endothelial cells [18] . This was important, because endothelial CD151 is essential for some endothelial cell functions, including angiogenesis [19] and inflammatory leucocyte recruitment [20] .
Tspan32-deficient platelets exhibited a remarkably similar phenotype to those lacking CD151 [21] . In vitro spreading and clot retraction were impaired, as was in vivo thrombus formation as measured using ferric chloride injury of mesenteric arterioles. Again the authors suggested that an αIIbβ3 outside-in signalling defect was responsible for this phenotype, and evidence was presented for an interaction The five tetraspanins depicted are those that have been demonstrated on platelets using specific antibodies, and tetraspanins are CD9 unless labelled otherwise; note that CD63 is expressed on lysosomes and intracellular granules in resting platelets. The interacting proteins are each known to be tetraspanin associated on other cell types and have more recently been identified on platelets by proteomics (J. Yang, E.J. Haining and M.G. Tomlinson, unpublished work). Specifically which tetraspanins these proteins interact with is not clear, with the exception of the direct CD151 interaction with α6β1. Note that integrin αIIbβ3 was also found to be tetraspanin-associated in some studies but not others [12] .
between αIIbβ3 and Tspan32 [21] . Similarly, an interaction with αIIbβ3 had been previously shown for CD151 [17] . These data suggest that these two tetraspanins are direct binding partners for αIIbβ3 and might enhance outsidein signalling by recruiting specific signalling proteins or promoting the active conformation of the integrin.
Interestingly, perhaps the best-defined role of any tetraspanin is that of CD151 as a specific partner for the four laminin-binding integrins, which include α6β1 on platelets [22] . Deletion of CD151, or mutation to prevent integrin binding, results in impaired integrin adhesion strengthening, signalling and trafficking, which leads to kidney failure in humans and mice [22] . However, the idea of such an intimate relationship between CD151/Tspan32 and the fibrinogenbinding integrin αIIbβ3 is controversial. We have been unable to detect an interaction between CD151 and αIIbβ3 on platelets in biochemical experiments that have shown a robust CD151-α6β1 association [11] . In addition, it is difficult to explain how 80 000 copies of αIIbβ3 could be regulated by two tetraspanins that combined are likely to be expressed at several-fold lower levels.
A question that arises from these knockout models is why are the platelet phenotypes quite subtle? In particular, why does deletion of the second most highly expressed platelet surface protein, CD9, yield a phenotype that is barely detectable? This is in marked contrast with the profound bleeding problems observed in the two other highly expressed proteins, αIIbβ3 and GPIb-IX-V, which result in the rare human bleeding disorders Glanzmann's thrombasthenia and Bernhard-Soulier syndrome, respectively [3] . The answer probably lies in the role of tetraspanins in generally finetuning the function of their associated proteins rather than being absolutely essential. Additionally, there is almost certain to be redundancy among the ten or more platelet tetraspanins, which is apparent in other cell types [4] . Indeed, CD9 is most closely related to the largely unstudied Tspan2 (47 % amino acid identity), which was recently found in a proteomic screen of the platelet cell surface [8, 12] . Similarly, CD151 has an unstudied relative, Tspan11, with which it shares 56 % amino acid identity.
Dissecting the microdomain
Historically, partner proteins were identified for a small number of tetraspanins by specific co-immunoprecipitation under cell lysis conditions that disrupted tetraspanintetraspanin interactions. These were followed by chemical cross-linking to capture direct interactions and/or imaging techniques to observe interactions in living cells [4] . More recently, several larger-scale proteomic studies have used tetraspanin immunoprecipitation, under conditions that maintain microdomain integrity, followed by MS to identify associated proteins [23, 24] . These studies have revealed several known and unknown tetraspanin-interacting proteins.
In our preliminary proteomic analyses of tetraspaninassociated proteins on platelets, we have identified the laminin-binding integrin α6β1, the scavenger receptor CD36, the choline transporter CD92 and the ectodomain sheddase ADAM10 (a disintegrin and metalloproteinase 10; Figure 2 ). None of these are surprising given that α6β1 interacts directly with CD151 [22] , that CD36 has been reported to interact with CD9 [25] and that both CD92 and ADAM10 have been identified as tetraspanin-associated in other cell types [23, 24, 26] . In addition to these, we have recently reported that the collagen receptor GPVI is tetraspaninassociated [11] , but we can find no evidence from coimmunoprecipitation studies that any of the following are tetraspanin-associated on platelets: integrins αIIbβ3, α2β1 and α5β1, GPIb-IX-V, Fcγ RIIA, PECAM-1 (platelet/endothelial cell adhesion molecule-1), CLEC-2 (C-type lectin 2), JAM (junctional adhesion molecule)-A or JAM-C (M.G. Tomlinson, unpublished work). However, the localization of α6β1 and GPVI is interesting, because the latter has been shown to bind laminin as well as its more recognized ligand collagen [27] . Laminin is highly expressed in the thin basement membrane that underlies endothelial cells, above the subendothelial region where the most thrombogenic forms of collagen reside. Could platelet tetraspanin microdomains therefore serve as platforms for optimal laminin adhesion that may be particularly important to repair minor damage to blood vessels, which exposes predominantly laminin? Similarly intriguing is the localization of ADAM10 and GPVI to tetraspanin microdomains, since the former can render platelets refractory to collagen by cleaving GPVI [28, 29] . So could tetraspanin microdomains be manipulated with antibodies or small molecules to induce GPVI shedding as a means of anti-platelet therapy?
Future directions
A current urgency in the tetraspanin field is to combine gene targeting of tetraspanins with the generation of new antibodies to identify specific partner proteins. Such studies will help to identify mechanisms responsible for observed phenotypes. In platelets, it will also be important to examine the role of tetraspanins in processes other than haemostasis and thrombosis, since platelets have emerged as important players in lymphatic development [30] , inflammation [1] and tumour metastasis [31] . Only then can we begin to think about perturbing tetraspanin microdomains with drugs to provide improved treatments for cardiovascular and other diseases.
